News & Publications News The Link Between Weight Loss Drugs and the U.S. Obesity RateMarch 18, 2025Seeking an Alternative Pathway to Weight LossFebruary 27, 2025Preventing Weight Loss Is Key to a Successful Cancer TreatmentFebruary 19, 2025The Threat Cachexia Poses to Heart MusclesFebruary 5, 2025Too Much Emphasis on Rapid Weight Loss Can Be HarmfulJanuary 29, 2025The Childhood Version of Cachexia Delivers Lasting ImpactsJanuary 23, 2025Treating Cachexia Would Not Only Benefit Patients But Also MedicareJanuary 6, 2025Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer PatientsDecember 20, 2024Obesity Drug Injections Pose Challenges for PatientsDecember 13, 2024GLP-1s and Vanishing Muscle MassDecember 4, 2024 View all News Publications Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in ratsNovember 7, 2024Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaOctober 28, 2023Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in rats.May 20, 2023Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects.May 20, 2023Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesMay 1, 2022Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogsMay 20, 2021Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07July 29, 2020Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexiaJune 16, 2020 View all Publications
Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer PatientsDecember 20, 2024
Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in ratsNovember 7, 2024
Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaOctober 28, 2023
Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in rats.May 20, 2023
Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects.May 20, 2023
Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesMay 1, 2022
Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07July 29, 2020
Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexiaJune 16, 2020
